Avizakimab, formerly known as BOS161721, represents a innovative medicinal approach to treating autoimmune diseases . This monoclonal agent selectively targets IL-18 , a vital cytokine implicated in the progression of several severe illnesses. Preclinical data have shown Avizakimab’s capacity to effectively inhibit IL-18 action, leading to decrea

Rosmantuzumab: A Deep Dive into OMP-131R10 Rosmantuzumab, formerly known by OMP-131R10, represents a new monoclonal antibody developed to block granulocyte-macrophage colony-stimulating FMS-like tyrosine kinase. Its mode of action involves selectively attaching to GM-CSF, preventing its engagement to its receptor on cells. Clinical research have e